West Pharmaceutical Services holds the cleaner structural position, with profitability as the main driver and valuation adding further support. Hikma Pharmaceuticals still has the edge on valuation, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels.
The lead is spread across profitability and growth, rather than sitting in one isolated gap. The overall score gap is 14 points in favour of West Pharmaceutical Services, Inc..
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
The pair sits on a clearly comparable long-term path, though it is not a near-twin match.
The strongest overlap appears in revenue stability and capital structure.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
West Pharmaceutical Services, Inc. occupies the cheaper side of the setup map, although Hikma Pharmaceuticals PLC still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Capital efficiency adds support, with a 4.8-point ROIC advantage.
Absolute pricing still looks more supportive for Hikma Pharmaceuticals, with a forward P/E that is 20.7 turns lower there.
The profitability edge is decisive, even though current pricing and valuation still lean somewhat toward Hikma Pharmaceuticals PLC.
Break down the HIK.L vs WST comparison across all dimensions with the full interactive tool.
Explore how HIK.L and WST each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.